Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Corn

Vascular Surgery Dallas, TX Medical Doctor

NPI 1427314780 CMS profile 4222918

621 N Hall St, Ste 727, Dallas, TX 75226

Open in the dashboard

General payments

$39,742

608 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Corn of Dallas, TX is reported in the CMS Open Payments database as having received $39,742 across 608 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,960 202
2024 General $4,203 104
2023 General $4,038 90
2022 General $3,228 83
2021 General $1,201 48
2020 General $640 27
2019 General $6,472 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Corn
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Robert Corn were reported at $19,960. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Robert Corn Vascular Surgery median Middle half National median
2019 $6,472 $796 $226–$2,363 $163
2020 $640 $348 $118–$1,110 $114
2021 $1,201 $471 $158–$1,421 $132
2022 $3,228 $725 $222–$2,183 $149
2023 $4,038 $836 $257–$2,440 $160
2024 $4,203 $909 $252–$2,619 $164
2025 $19,960 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $15,685 102 payments
  2. Medtronic Vascular, Inc. $4,536 27 payments
  3. W. L. Gore & Associates, Inc. $4,069 81 payments
  4. Silk Road Medical, Inc. $3,718 39 payments
  5. Endologix, Inc. $2,251 22 payments
  6. AxoGen $966 35 payments
  7. Aroa Biosurgery Incorporated $935 7 payments
  8. Tactile Systems Technology Inc $829 80 payments
  9. Bard Peripheral Vascular, Inc. $797 12 payments
  10. Cook Incorporated $628 1 payment
  11. Other $5,329 202 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,229 586 payments
  2. Travel and Lodging $6,503 19 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,760 2 payments
  4. Grant $3,250 1 payment
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $13,979 74 payments
  2. Endurant $3,810 6 payments
  3. ENROUTE Transcarotid Stent $2,708 31 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,708 31 payments
  5. Alto Abdominal Stent Graft System $1,713 15 payments
  6. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,106 10 payments
  7. ENROUTE 0.014 Guidewire $1,010 8 payments
  8. ENROUTE Transcarotid Stent System $1,010 8 payments
  9. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $1,010 8 payments
  10. ENHANCE Transcarotid Peripheral Access Kit $1,010 8 payments
  11. Other $17,946 626 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

191

Median for Vascular Surgery: 122

Drug cost

$31,904

Median for Vascular Surgery: $14,135

Branded share of claims

56%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 34 $30,632
Clopidogrel Clopidogrel Bisulfate Brand 59 $616
Gabapentin Generic 13 $233
Acetaminophen-Codeine Acetaminophen With Codeine Brand 14 $145
Ibuprofen Generic 20 $105
Cephalexin Generic 13 $75
Tramadol Hcl Generic 17 $71
Diazepam Generic 21 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 123 billing codes

Paid by Medicare

$165,663

Medicare's payments for the services billed

Medicare patients

304

Average age 72

Services billed

1,144

130 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 66%
Diabetes 60%
Ischemic heart disease 59%
Arthritis 57%
Heart failure 49%
COPD 33%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

608 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record